TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Seroconversion of household members
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: FVC change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS5)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose of Fedratinib Combined with Ivosidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Fedratinib Combined with Enasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reward positivity amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in level of hs-TnT >= 5ng/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade >= 2 cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total body clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Apparent steady-state volume of distribution (Vss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of IL1β, IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abnormalities on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in microbiome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in short chain fatty acids (SCFAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence and severity of treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence and severity of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Knee joint stiffness and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life impact on knee joint
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of pain measured by visual analog scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Rey Auditory Verbal Learning Test Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of radiotherapy-related gastrointestinal and urogenital tract adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of systemic parameters (Histamine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of systemic parameters (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of systemic parameters (Leukocytes formula)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of systemic parameters (IL1b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of systemic parameters (TNF alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of systemic parameters (IL6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of BAY3283142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCu of BAY3283142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BAY3283142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,u of BAY3283142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemically validated smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Health Risk of VLNCs (Absolute)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intraperitoneal pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in signs and symptoms of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of child anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in child problem behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Abilities Screening Instrument (CASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of participants with sustained HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSFI® score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apical shaping size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Irrigation activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of subjects with uncomplicated SAB who progress to complicated SAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of subjects with microbiologically documented relapse of SAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: T-Half
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patient experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of significant drug interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Breathlessness, Cough and Sputum Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Imaging contrast between the LC nucleus and the pontine tegmentum region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participant Satisfaction with the VR-enhanced Psychoeducational Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' System Usability and VR Headset Comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Professionals System Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of co-contraction of the ankle dorsi/plantar-flexor muscles during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symmetry of duration of co-contraction of the ankle dorsi/plantar-flexor muscles during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Concentration Time Curve (AUC) from Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Global Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PUCAI SCORE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFX-LEVELS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STEROIDS USE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Repeatability of SAT to skeletal muscle fatty acid uptake ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the highest TAMMV in internal carotid and middle cerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesic effects on active labor pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Borderline Personality Disorder Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of BPD-Related Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Circumference Reduction in Inches of the Waist, Hips, and Bilateral Thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut microbiota signature before and after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual task walking performance assessment- speed (m/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual task walking performance assessment- cadence (steps/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of dual task cost- gait speed (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced Phe intake in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Balance of nutrients and elements in the diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dyspepsia symptom change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Skin Fibrometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concentrations of pro-inflammatory and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of metallopeptidases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonitis Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of study participants maintaining involvement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fear of Progression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain Assessed by VAS at 48 Hours After Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSFI Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with immune-mediated AEs (imAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Chin volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of adverse events (AE)/ serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective pain perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neural response in the SPA circuitry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of patients correctly classified for advanced liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of Grade 3/4 Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: 25% Reduction in Benzodiazepine Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cessation of Benzodiazepine Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Psychological burdens experienced as caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes on caregiver's positive mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical function decline within 3 months from baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absolute change in average step counts at 3 months from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Providers Who Meet Eligibility Criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Providers who Consent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Providers who Complete Assigned Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Providers who Complete Assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to fascial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dextrose levels in synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dextrose level in subcutaneous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statistical concordance of serum biomarker results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glenohumeral internal rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: COVID-19 Anxiety Scale (CAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burn-Out de Maslach Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient preference of surgical drain placement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Prevention of post ERCP pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Sleep Onset Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Wake After Sleep Onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of complication
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Neuromuscular excitation of the Biceps Brachii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neuromuscular excitation of the Triceps Brachii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24-h urine oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to supervised physical exercise program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in help-seeking behaviour for depression care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Sensory Gating event-related potential (ERP) measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in behavioral measure of Social Responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in behavioral measure of Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: glaucoma screening uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Endothelial Cell Density Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent clinically abnormal physical exam
Endpoint domain: Adverse events/effects
Primary endpoint: Visual-analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients who died following bloodless cardiac surgery
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with unplanned reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with neurologic complication
Endpoint domain: Adverse events/effects
Primary endpoint: Stress relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of red-blood cell transfusions received by participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute change in Matsuda Insulin Sensitivity Index (Mat-ISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in urinary N-terminal telopeptide of type 1 collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in six meter walking test (6-MWT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Credibility/expectancy questionnaire (CEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient attitude towards utility of EMA and networks Scale (PAUEN)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Therapist attitude towards utility of EMA and networks Scale (TAUEN)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Evaluation Inventory (TEI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Extent of myocardial necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Neuroinflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Onco-Rash failure
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 vaccination rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent change in alkaline phosphatase (ALP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Single Dose Cmax of RVX000222 (apabetalone) and the Metabolites RVX000288 and RVX000404
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single Dose AUC of RVX000222 (apabetalone) and the Metabolites RVX000288 and RVX000404
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes spent in discussion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: H. pylori infection status in tonsillar tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to return to homeostatic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare service utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Crisis services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Multiple Sclerosis Physical Frailty Functional Assessment (MSPFFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local reactions after the vaccine/placebo dose
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analogue scale pain rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic events for 7 days after each vaccine/placebo dose
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant change from baseline in physical examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant change from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant change from baseline in electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically significant change from baseline in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Reduction in Cough Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum selenium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum zinc level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pruritus severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NDI score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sugar Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of aesthetic properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of functional properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of biological properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DAS-28-CRP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes